Navigation Links
Wide disparities in access to latest rheumatoid arthritis drugs across Europe
Date:3/6/2013

This means that 320 million people - 40% of Europe's population - who could benefit from treatment with disease modifying drugs (DMARDs) would struggle to get access to them, say the researchers.

DMARDs are extremely effective for the treatment of rheumatoid arthritis, and the European League Against Rheumatism (EULAR) recommends the use of synthetic DMARDs immediately after diagnosis to halt progress of the disease. But they are expensive.

The authors therefore surveyed key experts in 49 countries during 2011 about the availability, affordability and acceptability of both synthetic DMARDs, such as methotrexate and leflunomide, and biological DMARDs, such as infliximab and etanercept.

In all, 46 countries took part in the survey, which included those in Eastern Europe, Scandinavia, and Western Europe, as well as Turkey and Uzbekistan.

The responses revealed wide disparities in access to DMARDs. Six countries did not reimburse use of any of the five synthetic DMARDs included in the survey, and 10 countries did not pay for any biological DMARDs.

The cost of one year's treatment with a synthetic DMARD did not exceed any country's per capita GDP). But the cost of one year's treatment with a biological DMARD was higher than the per capita GDP of 26 countries, by as much as 11 times, the findings indicated.

That means that almost 40% of the population of Europe - equivalent to 320 million people - would have severely restricted access to biological DMARDs, say the authors.

Access was especially poor in countries in Central and Eastern Europe and those least well off, economically and socially, the findings showed.

The number of days a person on an average income would need to work to pay fhe full drug price of 30 days' treatment with a biological DMARD ranged from 12 days in Luxembourg to 190 in Romania.

Although it's not possible to draw definitive conclusions on the impact on health of restricted access, higher drugs prices were associated with increased disease activity and poorer physical functioning.

"Assuming needs for treatment with DMARDs are similar across countries, differences in access to medical treatment are unfair and raise alarming issues of inequity," write the authors.

Wealthy Western countries continually debate the budgetary impact of expensive drugs, but unaffordability in low income countries is rarely discussed, they note.

The cheap cost of labour means that these expensive drugs are rarely going to be considered a return on investment, in terms of improved productivity, they add, and drug pricing in Europe should be revised, say the authors.


'/>"/>

Contact: Emma Dickinson
edickinson@bmjgroup.com
44-020-738-36529
BMJ-British Medical Journal
Source:Eurekalert

Related medicine news :

1. Praeclarus Press Launches the One Every 21 Seconds Campaign to Increase Awareness on the Role of Breastfeeding in Reducing Racial/Ethnic Disparities in Infant Mortality
2. Hospital Type Linked to Racial Disparities in Kids With Appendicitis Complication
3. Study reports racial disparities in pediatric appendicitis treatment tied to hospital type
4. Racial Disparities Still Seen in Use of Breast Cancer Treatments
5. Are there racial disparities in osteoporosis screening and treatment?
6. Policy considerations pose options for leaders to reduce costly disparities in diabetes
7. 2 NIH studies show power of epidemiology research; Underscore need to address health disparities
8. Orange County partnership to target cancer health disparities
9. Ethnic disparities in breast cancer survival remain despite socioeconomic similarities
10. AACR, Komen for the Cure honor researcher with lecture on science of cancer health disparities
11. Vanderbilt-led study reveals racial disparities in prostate cancer care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Lakes, NJ (PRWEB) , ... December 05, 2016 ... ... recording studio teaming up on new songs with prolific Songwriter-Producer Corey “Chorus” Gibson ... Foxx, Kelly Rowland, Ciara, Brandy…just to name a few.     https://twitter.com/coreychorus , ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... moisture measurements are consistently correct. However, regular performance testing is often neglected ... offers a solution: SmartCal™ . This innovative test substance offers a ...
(Date:12/4/2016)... York, NY (PRWEB) , ... December 03, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – hosted its first Swirl: A Wine Tasting Event in New York ...
(Date:12/4/2016)... ... 04, 2016 , ... "Pro3rd Displace is a set of ... displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... of design styles that include both left aligned and right aligned options for ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Lori G. ... Traurig, LLP’s Atlanta office, will speak at the American Conference Institute’s 21st Drug ... Traurig is also a Lead Sponsor of the conference. , Cohen, who chairs the ...
Breaking Medicine News(10 mins):
(Date:12/5/2016)... -- M ichael Moore ... Chairman   Mission Therapeutics, a drug discovery and ... treat cancer, neurodegenerative and other diseases, announces that Dr ... January 1 st 2017. Dr Colin Goddard ... in July 2015. Michael Moore , Mission,s Founder Chairman, ...
(Date:12/4/2016)... 3, 2016 Johnson & Weaver, LLP announces that ... of Zimmer Biomet Holdings, Inc. (NYSE: ZBH ) ... 31, 2016 (the "Class Period"). Zimmer Biomet provides ... orthopaedic reconstructive products, such as knee and hip reconstructive products. ... , , ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the ... SelG1), an anti-P-selectin antibody, reduced the median annual rate ... to placebo (1.63 vs 2.98, p=0.010) in patients with ... that the data are being featured in the official ... of Hematology (ASH) Annual Meeting and presented during the ...
Breaking Medicine Technology: